By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...

As an anti-HER2 ADC, preliminary findings from IBI354 have demonstrated encouraging objective response rates (ORR) and disease control rates (DCR) in PROC. Furthermore, IBI354 exhibits a superior ...